The interaction between the stroma and primary tumors, or their metastases, is essential for fixation of oncogenic mutations. This cross-talk is mediated by a large group of growth factors, whose prototype is the neuregulin family of EGF-like molecules. Neuregulins and their membrane receptors of the ErbB group of transmembrane tyrosine kinases constitute a signaling network. His previous analyses characterized a heterodime comprising a kinase-defective neuregulin receptor (ErbB-3) and a ligand-less oncogenic co-receptor (ErbB-2) as the most potent receptor species of the network. He hypothesizes that a neuregulin-driven ErbB-2.ErbB-3 heterodimer is a major proliferative engine of epithelial tumors. The following lines of research will test this scenario and its implications to the development of therapeutic strategies: (i) Ligands and their antagonists: Apparently, the heterodimer is a promiscuous receptor for multiple stromal ligands, probably because they all share a bivalent structure. New ligands that will become available through the Human Genome Project will be synthesized and tested for binding to the heterodimer or to an Erbb-2 homodimer. The information accumulated will be used to design antagonists of the heterodimer. (ii) Signaling pathways and their inhibitors: The biochemical mechanisms underlying the extremely potent proliferative action of the heterodimer will be investigated by using a yeast two-hybrid screen and a chimeric receptor approach. Synergy between immunotherapy, chemotherapy and inhibitors of the identified pathway(s) will be examined in model systems of tumor growth. (iii) Intracellular routes and their modifiers: He hypothesizes that endocytic routing of the heterodimer to recycling, rather than to degradation, contributes to its signaling potency. This model will be examined by using mutant receptors, and the recycling machinery characterized in details. The suspected cancer-inhibitory activity of drugs interfering with ErbB routing will be tested in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA072981-04
Application #
6128866
Study Section
Pathology B Study Section (PTHB)
Program Officer
Freeman, Colette S
Project Start
1997-04-25
Project End
2005-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
4
Fiscal Year
2000
Total Cost
$179,550
Indirect Cost
Name
Weizmann Institute of Science
Department
Type
DUNS #
City
Rehovot
State
Country
Israel
Zip Code
76100
Lauriola, Mattia; Enuka, Yehoshua; Zeisel, Amit et al. (2014) Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat Commun 5:5073
Schneider, Marlon R; Yarden, Yosef (2014) Structure and function of epigen, the last EGFR ligand. Semin Cell Dev Biol 28:57-61
Maron, Ruth; Schechter, Bilha; Mancini, Maicol et al. (2013) Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A 110:15389-94
Mahlknecht, Georg; Maron, Ruth; Mancini, Maicol et al. (2013) Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A 110:8170-5
Ferraro, Daniela A; Gaborit, Nadège; Maron, Ruth et al. (2013) Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A 110:1815-20
Pradeep, C-R; Kostler, W J; Lauriola, M et al. (2012) Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 31:907-17
Tarcic, Gabi; Avraham, Roi; Pines, Gur et al. (2012) EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 26:1582-92
Lindzen, M; Carvalho, S; Starr, A et al. (2012) A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 31:3505-15
Avraham, Roi; Yarden, Yosef (2012) Regulation of signalling by microRNAs. Biochem Soc Trans 40:26-30
Bossel Ben-Moshe, Noa; Avraham, Roi; Kedmi, Merav et al. (2012) Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets. Nucleic Acids Res 40:10614-27

Showing the most recent 10 out of 59 publications